SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB


 [x]     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934.

                  For the quarterly period ended April 30, 1997

                                       OR

 [ ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         ACT OF 1934.

        For the transition period from                to
                                      ----------------  ----------------

                         Commission file number 2-86360



                                INFORMEDICS, INC.
        (Exact name of small business issuer as specified in its charter)

              Oregon                                  93-0750571

       (State of incorporation)          (I.R.S. Employer Identification No.)



                              4000 Kruse Way Place
                                Bldg 3, Suite 300
                              Lake Oswego, OR 97035
                              ---------------------
                    (Address of principal executive offices)

                    Issuer's telephone number: (503) 697-3000

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the Securities  Exchange Act of 1934 during the preceding
12 months (or for such shorter  period that the issuer was required to file such
reports),  and (2) has been subject to such filing  requirements for the past 90
days. Yes /X/ No / /

Number of shares of Informedics, Inc. $.01 par value common stock outstanding as
of May 30, 1997: 2,650,307.


<PAGE>




                                INFORMEDICS, INC.


                         Part I - Financial Information




          The   information   included  herein  is  unaudited.   However,   such
 information  reflects all adjustments  (consisting solely of normal,  recurring
 adjustments)  which are, in the  opinion of  management,  necessary  for a fair
 presentation of the results of operations for the interim periods.  The interim
 financial  information and notes thereto should be read in conjunction with the
 Company's  latest annual report on Form 10-KSB.  The results of operations  for
 the six months ended April 30, 1997 are not  necessarily  indicative of results
 to be expected for the entire year.



<PAGE>



INFORMEDICS,  INC.
STATEMENTS OF OPERATIONS

<TABLE>
<CAPTION>

                                                    Three Months Ended                                 Six Months Ended
                                                         April 30,                                       April 30,

                                         -----------------------------------------     ---------------------------------------
                                                1997                1996                      1997               1996

                                         ------------------    -------------------     -------------------   -----------------
<S>                                           <C>                    <C>                    <C>                  <C>    

REVENUE:
Product Sales                                  $  274,249             $  390,478             $  424,010           $  817,358
Customer Service and Support                      640,985                894,226              1,336,920            1,751,527
                                         ------------------    -------------------    -------------------    -----------------

Total Revenue                                     915,234              1,284,704              1,760,930            2,568,885
                                         ------------------    -------------------     ------------------    -----------------

COSTS AND EXPENSES:
Cost of Products Sold                              25,450                133,416                 53,661              367,241
Cost of Customer Service and Support
                                                  471,916                765,852                973,002            1,476,711
Selling & Administrative Expenses                 521,721                510,957              1,006,868            1,148,949
Depreciation & Amortization                       100,627                128,159                202,237              215,357
                                         ------------------    -------------------     ------------------    -----------------

Total Costs and Expenses                        1,119,714              1,538,384              2,235,768            3,208,258
                                         ------------------    -------------------     ------------------    -----------------

Operating  Loss                                 (204,480)              (253,680)              (474,838)            (639,373)
                                         ------------------    -------------------     ------------------    -----------------

OTHER INCOME (EXPENSE):
Interest Expense                                    (686)                   ----                (4,521)                  (7)
Interest Income                                    11,019                  4,561                 19,699                8,665
Other Income                                        6,430                    329                 10,099                  115
                                         ------------------    -------------------     ------------------    -----------------

Total Other Income                                 16,763                  4,890                 25,277                8,773
                                         ------------------    -------------------     ------------------    -----------------

LOSS BEFORE INCOME TAXES                        (187,717)              (248,790)              (449,561)            (630,600)

INCOME TAX                                            ---               (94,752)                    ---            (240,715)
BENEFIT
                                         ------------------    -------------------     ------------------    -----------------

NET LOSS                                     $  (187,717)           $  (154,038)           $  (449,561)         $  (389,885)
                                         ==================    ===================     ==================    =================

Weighted Average Number of Common
Shares Outstanding and Common Stock
Equivalents Outstanding
                                                2,650,307              2,645,208              2,650,307            2,644,296
                                         ==================    ===================     ==================    =================



LOSS PER SHARE                               $     (0.07)         $       (0.06)           $     (0.17)       $       (0.15)
                                         ==================    ===================     ==================    =================


See Notes to Financial Statements.
</TABLE>

<PAGE>

INFORMEDICS, INC.
BALANCE SHEETS
<TABLE>
<CAPTION>

                                                                     April 30,             October 31,
ASSETS                                                                 1997                    1996
                                                                 -------------------    -------------------

<S>                                                                    <C>                    <C>

CURRENT ASSETS:

Cash                                                                    $  166,152             $  323,217
Accounts Receivable, less allowance
   for doubtful accounts of $  61,000 in
   1997 and $ 28,439 in 1996                                               492,398                681,303
Inventories                                                                 14,876                 23,833
Prepaid Expenses and Other Current Assets                                   31,336                 36,150
Deferred Income Taxes                                                      159,251                182,483
Current Portion of Long-Term                                                11,928                 11,928
Receivable
Current Portion of Notes Receivable                                        335,174                 54,095
                                                                 -------------------    -------------------

Total Current Assets                                                     1,211,115              1,313,009
                                                                 -------------------    -------------------


FIXED ASSETS:

Furniture and Fixtures                                                     134,282                134,282
Machinery and Equipment                                                    596,256                583,961
Automobiles                                                                 29,138                 29,138
Leasehold Improvements                                                      26,738                 20,442
Other Fixed Assets                                                         139,781                136,805
                                                                 -------------------    -------------------
                                                                           926,195                904,628
Less accumulated depreciation and amortization                             744,108                672,300
                                                                 -------------------
                                                                                        -------------------

Total Fixed Assets                                                         182,087                232,328
                                                                 -------------------    -------------------


OTHER ASSETS:

Long-Term Account Receivable                                                36,778                 42,742
Notes Receivable                                                               ---                305,102
Software Development Costs,
   less accumulated  amortization of $ 663,924 in
   1997 and $ 542,884 in 1996                                              242,198                305,415
Covenants Not to Compete,
   less accumulated amortization of $ 487,415  in 1997
   and $ 479,698 in 1996                                                     6,630                 14,348
Deferred Income Taxes, less valuation reserve of
    $ 185,089 in 1997                                                      636,292                613,060
Other                                                                       39,874                 41,816
                                                                 -------------------    -------------------
                                                                                                           

Total Other Assets                                                         961,772              1,322,483
                                                                 -------------------    -------------------
                                                                                                           

TOTAL ASSETS                                                          $  2,354,974           $  2,867,820
                                                                 ===================    ===================
                                                                                                           
See Notes to Financial Statements

</TABLE>
<PAGE>


INFORMEDICS, INC.
BALANCE SHEETS
<TABLE>
<CAPTION>


                                                                        April 30,             October 31,
   LIABILITIES AND STOCKHOLDERS' EQUITY                                   1997                   1996
                                                                    ------------------     ------------------
                                                                                                             
<S>                                                                      <C>                     <C>
   CURRENT LIABILITIES:

   Accounts Payable and Accrued Expenses:
      Trade Accounts                                                      $  113,044             $  115,543
      Customer Deposits                                                       11,255                  4,120
      Accrued Wages, Payroll Taxes and Employee
         Benefits                                                            125,174                175,285
      Other Accrued Liabilities                                                8,541                    767
   Revolving Line of Credit (Note 2)                                         100,000                125,000
   Deferred Revenue                                                        1,289,537              1,274,687
   Current Portion of Deferred Rent                                           13,033                 13,033
   Current Portion of Deferred Gain on Sale of Assets                         98,073                 19,615
                                                                    ------------------     ------------------
                                                                                                             

   Total Current Liabilities                                               1,758,657              1,728,050

   LONG-TERM OBLIGATIONS:

   Deferred Rent                                                              23,894                 30,411
   Deferred Gain on Sale of Assets                                               ---                 87,375
                                                                    ------------------     ------------------
                                                                                                             
   Total Current Liabilities and
      Long-Term Obligations                                                1,782,551              1,845,836
                                                                    ------------------     ------------------
                                                                                                             

   STOCKHOLDERS' EQUITY:

   Preferred Stock, $ .01 par value:
      authorized 5,000,000 shares;
      no shares outstanding                                                      ---                   ----
   Common Stock, $.01 par value:
      authorized 15,000,000 shares;
      shares outstanding:  2,650,307 in 1997 and 1996                         26,503                 26,503
   Capital in Excess of Par Value                                          1,914,213              1,914,213
   Note Receivable from Stockholder                                         (22,000)               (22,000)
   Accumulated Deficit                                                   (1,346,293)              (896,732)
                                                                    ------------------     ------------------
                                                                                                             

   Total Stockholders' Equity                                                572,423              1,021,984
                                                                    ------------------     ------------------
                                                                                                             

   TOTAL LIABILITIES AND STOCKHOLDERS'
      EQUITY                                                            $  2,354,974           $  2,867,820
                                                                    ==================     ==================
                                                                                                             

   See Notes to Financial Statements.


</TABLE>

<PAGE>


INFORMEDICS, INC.
STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>

                                                                              Six Months Ended April 30,

                                                                       -----------------------------------------
                                                                           1997                   1996
                                                                       -----------------------------------------


CASH FLOWS FROM OPERATING ACTIVITIES:
<S>                                                                       <C>                    <C>

  Net loss                                                                 $  (449,561)           $  (389,885)

ADJUSTMENTS  TO RECONCILE  NET LOSS TO NET
CASH  PROVIDED BY (USED IN) OPERATING ACTIVITIES:
 Depreciation and Amortization                                                  202,237                215,357
 Provision for losses on (write off of) accounts receivable                      32,561               (16,234)
 Deferred Income Taxes                                                              ---              (241,521)
 Tax benefits from stock options exercised                                          ---                    796
 Gain on Sale of Assets                                                         (8,917)                    ---
 Changes in Assets and Liabilities:
   Accounts Receivable                                                          162,308                 66,377
   Income taxes receivable                                                          ---                 29,087
   Inventories                                                                    8,957                 38,093
   Prepaid Expenses and Other Current Assets                                      4,814                 52,367
   Accounts Payable and Accrued Expenses                                       (37,701)                 44,804
   Notes Receivable                                                              24,023                    ---
   Deferred Revenue                                                              14,850                258,337
   Deferred Rent                                                                (6,517)                (6,516)
                                                                       ------------------     ------------------
Net cash provided by (used in) operating activities                            (52,946)                 51,062
                                                                       ------------------     ------------------
                                                                                                                

INVESTING ACTIVITIES:
 Property additions                                                            (23,238)               (57,253)
 Capitalized software development costs                                        (57,823)              (135,477)
 Other                                                                            1,942                  3,287
                                                                       ------------------     ------------------
 Net cash used in investing activities                                         (79,119)              (189,443)
                                                                       ------------------     ------------------
                                                                                                                

FINANCING ACTIVITIES:
 Decrease in revolving line of credit                                          (25,000)                    ---
 Proceeds from issuance of common stock                                             ---                  2,997
                                                                       ------------------     ------------------
 
 Net cash provided by (used in) financing activities                           (25,000)                  2,997
                                                                       ------------------     ------------------

NET DECREASE IN CASH                                                          (157,065)              (135,384)

CASH AT BEGINNING OF PERIOD                                                     323,217                534,260
                                                                       ------------------     ------------------

CASH AT END OF PERIOD                                                        $  166,152              $ 398,876
                                                                       ==================     ==================

</TABLE>

<PAGE>


 INFORMEDICS, INC.
STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>

                                                                         Six Months Ended April 30,
                                                                 -------------------------------------------
                                                                        1997                    1996
                                                                 -------------------------------------------
                                                                                                            
<S>                                                                      <C>                    <C>

Supplemental Disclosures of Cash Flow
 Information:

Cash paid for:
 Interest                                                                $  4,521               $     7

 Income Taxes Received                                                       ----               (29,077)



















</TABLE>


See Notes to Financial Statements.



<PAGE>


INFORMEDICS, INC.
NOTES  TO FINANCIAL STATEMENTS


1.        SIGNIFICANT ACCOUNTING POLICIES

         Industry Segment
         ----------------

          The Company derives its revenue solely from the sales and servicing of
          microcomputer software and related hardware.

         Inventories
         -----------

          Inventories  are  stated  at the  lower  of cost or  market.  Specific
          identification is used to determine the costs of hardware and software
          inventory.

         Fixed Assets
         ------------

          Fixed Assets are stated at cost,  less  accumulated  depreciation  and
          amortization.  The  costs of fixed  assets  are  depreciated  over the
          estimated  useful  lives (two to five  years) of the assets  using the
          straight-line  method.  Leasehold  improvements are amortized over the
          term of the lease (five years).

         Customer Service and Support Revenue
         ------------------------------------

          Customer  service and support revenue  represents  revenue earned from
          hardware and software maintenance contracts, training, installation of
          new systems,  and general  software  support and programming  services
          provided to customers.  Under  renewable  maintenance  contracts,  the
          Company  provides,  for a term of  generally  not more  than one year,
          essentially all maintenance and repairs  resulting from the normal and
          intended  use  of  its  products.   Deferred  revenue  on  maintenance
          contracts is amortized  by the  straight-line  method over the life of
          the contracts.

         Revenue Recognition
         -------------------

          Revenue from sales of software and hardware is generally recorded when
          the product is shipped.  Revenue from custom software products,  which
          are  marketed  to  customers   primarily   under   perpetual   license
          arrangements,  is recorded at the time the  product is  installed  and
          accepted by the customer. Revenue from services other than maintenance
          contracts is recognized as performed.

        Income Taxes
        ------------

         Income taxes are accounted  for using the  methodology  established  by
         Statement of Financial Accounting Standards (SFAS) No.109,  "Accounting
         for Income Taxes",  which requires an asset and a liability approach to
         financial  accounting and reporting for income taxes.  Deferred  income
         tax assets and  liabilities  are computed for  differences  between the
         financial  statement and tax bases of assets and liabilities  that will
         result in taxable or  deductible  amounts in the  future.  A  valuation
         allowance is established  when necessary to reduce  deferred tax assets
         to amounts expected to be realized, based on enacted tax laws and rates
         applicable  to the  periods in which the  differences  are  expected to
         affect taxable income. Income tax expense or benefit is the tax payable
         or  refundable  for the  period,  plus or minus the  change  during the
         period in deferred tax assets and liabilities.



<PAGE>


INFORMEDICS, INC.
NOTES  TO FINANCIAL STATEMENTS


         Software Development Costs
         --------------------------

          Certain software development costs are being capitalized and amortized
          over the estimated  economic life of the software,  on a straight-line
          method,  commencing  when each product or enhancement is available for
          general release.  Amortization using the straight-line  method for the
          six-month  periods  ended  April 30, 1997 and 1996 was $ 121,040 and $
          80,693, respectively.

         Covenants Not to Compete
         ------------------------

         Covenants  not to  compete  are  stated at the  estimated  value of the
         consideration  given for the covenants  (including the present value of
         any future payments to be made under each agreement),  less accumulated
         amortization.  The costs of the covenants are being amortized over four
         or seven years,  using the straight-line  method.  Amortization for the
         six-month  periods  ended  April  30,  1997 and 1996 was $ 7,718  and $
         38,582, respectively.

         Loss Per Share
         --------------

         Loss per share is computed on the basis of weighted  average  number of
         shares outstanding plus common stock equivalents which would arise from
         the exercise of stock  options and warrants.  Common stock  equivalents
         are  excluded  from the  calculation  of net loss per share for the six
         months ended April 30, 1997 and 1996, as they are antidilutive.

         Cash and Cash Equivalents
         -------------------------

          The Company considers cash on hand, deposits in bank and highly liquid
          debt  instruments  purchased  with  original  maturity  dates of three
          months or less, as cash.

          Accounting Changes
          ------------------

          In October  1995,  the  Financial  Accounting  Standards  Board issued
          Statement  of   Financial   Accounting   Standards   (SFAS)  No.  123,
          "Accounting for Stock-Based Compensation".  This statement establishes
          an  alternative  method of  accounting  that requires  recognizing  as
          expense the fair value of employee stock options and other stock-based
          awards at the grant date. SFAS No. 123 also allows the continuation of
          the current  accounting  treatment  under  which the Company  does not
          recognize  compensation  expense  for the stock  options  it awards to
          employees. Since the Company is electing to retain its current method,
          it will be  required  to  present  pro forma  disclosures  in its 1997
          annual financial statements as if the fair value based method had been
          applied.

          In February  1997,  the Financial  Accounting  Standards  Board issued
          Statement of Financial  Accounting Standards (SFAS) No. 128, "Earnings
          per Share".  SFAS 128, requires all companies whose capital structures
          include convertible securities and options to make a dual presentation
          of basic  and  diluted  earnings  per  share  (EPS) on the face of the
          income  statement and requires  additional  disclosures  regarding the
          computation  of EPS. The new standard  becomes  effective  for interim
          statements  issued after December 15, 1997. The effect on earnings per
          share for all periods reported is immaterial.



<PAGE>


INFORMEDICS, INC.
NOTES  TO FINANCIAL STATEMENTS

         Reclassifications
         -----------------

         Certain  prior year  amounts have been  reclassified  to conform to the
         current year presentation.  These  reclassifications  have no effect on
         net income.


2.        CREDIT AGREEMENTS

         In  April  1997  the  Company  renewed  its  revolving  line of  credit
         agreement with United States National Bank of Oregon ("USNB"). The line
         of credit  agreement  allows the Company to borrow up to  $700,000  and
         requires the Company to maintain certain financial  ratios.  All assets
         of the  Company are pledged as  security  for the loan.  The  agreement
         requires  the  Company to make  monthly  interest-only  payments on all
         amounts outstanding under the agreement.  The interest rate varies from
         1% to 2% above  USNB's prime  interest  rate.  On April 30,  1997,  the
         Company's balance  outstanding under the agreement was $100,000 and the
         interest rate was 9.50%. The agreement expires April 15, 1998.


<PAGE>


INFORMEDICS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

THE FOLLOWING  DISCUSSION  INCLUDES CERTAIN  FORWARD-LOOKING  STATEMENTS.  THOSE
STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES, WHICH COULD CAUSE ACTUAL
RESULTS  TO  DIFFER  MATERIALLY  FROM  THE  EXPECTATION  STATED,  INCLUDING  THE
FOLLOWING: SLOWER THAN EXPECTED SALES OF INFORMEDICS' PRODUCTS, DETERIORATION OF
BUSINESS  CONDITIONS  GENERALLY OR  SPECIFICALLY  IN THE  HEALTH-CARE  INDUSTRY,
REGULATORY CHANGES INVOLVING HEALTH CARE,  COMPETITIVE FACTORS,  PRICE PRESSURES
AND HIGHER THAN EXPECTED TURNOVER IN KEY PERSONNEL.

Highlights
----------
On October  31,  1996,  the Company  sold  certain  assets of its  ClinicManager
product line to Adaptive  Health Systems of Washington,  Inc.  (`Adaptive').  In
April  1997  certain  conditions  of the sale were  satisfied,  resulting  in an
acceleration of the note receivable payments due from Adaptive.  On May 8, 1997,
the Company  received  $406,500 from  Adaptive to pay off the note.  The Company
expects to recognize a gain of  approximately  $166,000 during its third quarter
ended July 31, 1997 relating to the funds received from Adaptive in May 1997.

The sale of the  ClinicManager  product  line and other  cost  cutting  measures
resulted in improved operating  results,  as the Company reduced its loss before
income  taxes for the  second  quarter  and the first six  months of 1997,  when
compared to the same periods in 1996.  The loss before  income  taxes  decreased
from $248,790 in second quarter 1996 to $187,717 in second quarter 1997 and from
$630,600  for the first six months of 1996 to $449,561  for the first six months
of 1997.

The  elimination of the  ClinicManager  product line from the Company's  revenue
base  resulted  in a decrease in both  product  sales and  customer  service and
support  revenue for the second quarter and the first six months of 1997.  Total
revenue  decreased  from  $1,284,704  and  $2,568,885 for the second quarter and
first six months of 1996,  respectively,  to  $915,234  and  $1,760,930  for the
second quarter and first six months of 1997, respectively.

The  Company  did not record an income tax  benefit  in fiscal  1997  because it
established a valuation reserve against its deferred tax assets in the amount of
$185,089 for the six month period.  This  resulted in the Company's  reporting a
higher loss (after taxes) for second quarter 1997 of $187,717 or $0.07 per share
compared to $154,038 or $0.06 per share for second  quarter 1996.  For the first
six months of 1997,  the  Company  reported a net loss of  $449,561 or $0.17 per
share  compared  to a net loss of  $389,885 or $0.15 per share for the first six
months of 1996.

Results of Operations - Material Changes
----------------------------------------

The decrease in product sales of $116,229 for second quarter 1997 as compared to
second  quarter 1996  resulted  from the loss of revenue from the  ClinicManager
product line,  offset in part by an increase in laboratory system product sales.
The  decrease  in  product  sales of  $393,348  for the first six months of 1997
resulted  from the loss of revenue  from the  ClinicManager  product  line and a
decrease in  laboratory  system  product sales during the first quarter of 1997.
During the second quarter of 1997, the Company hired additional  salespersons to
increase  product  sales in future  periods.  Management  believes that products
sales  for  1997  will  continue  to lag  1996  results  until  sales of its new
IntraMed.net product line exceed previous ClinicManager sales levels.

The  decrease in customer  service and support  revenue of $253,241 and $414,607
for the second quarter and first six months of 1997, respectively, when compared
to the  same  periods  in  1996,  resulted  from  a loss  of  revenue  from  the
ClinicManager  product line, a decrease in the number of customers who purchased
the  Company's  hardware  support  services  and a reduction in revenue from not
charging  laboratory  systems'  customers a regulatory  fee in 1997 as it did in
1996. In the second quarter of 1997, the Company began marketing a new technical
support  service to help  replace the  revenue  lost from the  hardware  support
services.  Management believes that customer service and support revenue for the
remainder of 1997 will continue to be less than comparable periods in 1996.

A decrease in hardware sales of $124,771 and $367,739 for the second quarter and
first six months of 1997,  respectively,  resulted  in a decrease in the cost of
products sold. The decrease in hardware sales resulted from the

<PAGE>

INFORMEDICS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

elimination  of revenue from the  ClinicManager  product line, a decrease in the
number of  laboratory  systems  sold in the first  quarter,  and a  decrease  in
hardware  sales  related to the  Company's lab order entry product line as Quest
Diagnostics, Inc., elected to purchase its hardware from another vendor.

The decrease of $293,936  and  $503,709 in cost of customer  service and support
for the second quarter and first six months of 1997, respectively, resulted from
a  reduction  in  staff  and  other  costs  as a  result  of  the  sale  of  the
ClinicManager product line. Management anticipates that cost of customer service
and support for the  remainder of 1997 will be less than  comparable  periods in
1996.

The  increase of $10,764 in selling and  administration  expenses for the second
quarter of 1997 compared to the second quarter of 1996,  resulted from increases
in sales  and  marketing  costs  and in bad debt  expense,  offset  in part by a
decrease in rent  expense.  The increase in sales and marketing  costs  resulted
from hiring additional  salespersons,  placing more advertisements and incurring
additional  travel  related  costs to  market  the  Company's  IntraMed.net  and
LifeLine  product lines.  The increase in bad debt expense resulted from setting
up a reserve for one customer who is experiencing  financial  difficulties.  The
decrease in rent expense  resulted from the Company  subletting  part of the its
office space.  Management  anticipates that selling and administration  expenses
will be higher during the remainder of 1997 than comparable  periods in 1996, as
the Company plans to continue its expanded  sales and  marketing  efforts of its
IntraMed.net and LifeLine product lines.

Liquidity - Capital Resources
-----------------------------

The  Company's  cash  position  decreased  from  $323,217 on October 31, 1996 to
$166,152  on  April  30,  1997,  as the  Company  used  $52,946  of its cash for
operating activities, $79,119 for investing activities and $25,000 for financing
activities. As discussed earlier, the Company received $406,500 from Adaptive on
May 8, 1997 in full payment of the  Company's  note  receivable.  Based upon the
anticipation of higher product sales, reduced operating expenses and the receipt
of funds from  Adaptive,  management  believes that the  Company's  current cash
position and available  funds under its revolving line of credit  agreement will
be sufficient to fund its operating and investment  activities for the remainder
of fiscal 1997.

Continuing  losses  resulted in a negative  working capital of $547,542 on April
30, 1997 as compared  to a negative  working  capital of $415,041 on October 31,
1996. Excluding the deferred revenue liability,  which is a liability for future
services, the Company's working capital on April 30, 1997 was $741,995, compared
to $859,646 on October 31, 1996.

Capital  expenditures  for  property  additions  were  $23,238 for the first six
months  of 1997  compared  to  $57,253  for the first  six  months of 1996.  The
decrease resulted from management's  decision to reduce capital  expenditures in
1997.  Management  anticipates that capital  expenditures for property additions
for remainder of 1997 will continue to be less than 1996 amounts.

Capitalized  software development costs amounted to $57,823 and $135,477 for the
first six months of 1997 and 1996, respectively.  The decrease resulted from the
reduction of the software  development  costs associated with the  ClinicManager
product.  Management  anticipates that capitalized software development cost for
the remainder of 1997 will continue to be less than 1996 amounts.

In April 1997 the Company  renewed its $700,000  uncommitted  revolving  line of
credit with the Company's  bank. At April 30, 1997, the Company's  balance under
this line of credit was  $100,000.  All of the assets of the Company are pledged
as  security  for the line of  credit.  Terms of the  revolving  line of  credit
require the Company to maintain certain financial ratios. As of the date of this
Quarterly  Report,  the Company has maintained the required ratios.  The line of
credit expires April 15, 1998.



<PAGE>


                                INFORMEDICS, INC.

                           Part II - Other Information


 Item 4.   Submission of Matters to a Vote of Security Holders
           ---------------------------------------------------


     (a) The 1997 Annual Shareholders Meeting was held March 14, 1997.

     (b) The following directors were re-elected at the meeting with the
         following votes:

                                        Votes For                 Votes Withheld
                                        ---------                 --------------

        John Tortorici                     2,297,385                 74,532
        Charles V. Dexter                  2,317,435                 54,482
        Richard D. Glaser                  2,296,435                 75,482
        Ronald P. Witcosky                 2,307,435                 64,482
        Gerald P. Kelly                    2,322,635                 49,282

     (c) The following other matters were approved at the meeting:

         Ratification of the appointment of Deloitte & Touche LLP as independent
         public accountants for fiscal 1997.

                    For                    Against                   Abstain
                    ---                    -------                   -------

                  2,340,500                 15,200                    16,217


 Item 6.   Exhibits and Reports on Form 8-K
           --------------------------------

                    (a)  Exhibits.

                          27        Financial Data Schedule

                    (b)   Reports on Form 8-K.  On March 26,  1997,  the Company
                          filed Form 8-K, dated March 14, 1997. In the Form 8-K,
                          the Company  reported the  resignation  of Mr.  Gerald
                          Kelly as President and Chief Operating  Officer and as
                          director of the Company.






<PAGE>



                                   SIGNATURES



Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                        INFORMEDICS, INC.
                                        (Registrant)


Date   June 11, 1997                    By /s/ John Tortorici
      ---------------                      -------------------------------------
                                           John Tortorici, Chairman, President
                                           and Chief Executive Officer



Date   June 11, 1997                    By /s/ Dale E. Conner
      ---------------                      -------------------------------------
                                           Dale E. Conner, Vice President
                                           and Chief Financial Officer


<PAGE>


                                   FORM 10-QSB

                                  Exhibit Index

Exhibit

  27       Financial Data Schedule